Altimmune, Inc. (NASDAQ: ALT) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT ALTIMMUNE, INC.

Altimmune, Inc. (NASDAQ: ALT)
Listen to this Section


$2.77
-0.1050 ( -3.66% ) 2.2M

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Clinical Trial Pipeline Stages


Drug Name Stage
Pemvidutide (ALT-801) (GLP-1R/GCGR)DetailsNon-alcoholic steatohepatitis , Non-Alcoholic Fatty Liver Disease, metabolic dysfunction-associated steatohepatitisBig Mover™Suspected Mover™Susp. Mover™ Phase 2b
Pemvidutide (ALT-801) (GLP-1R/GCGR)Detailsmetabolic dysfunction-associated steatohepatitis Phase 2b
Pemvidutide (ALT-801) (GLP-1R/GCGR)DetailsObesity Phase 2
Pemvidutide (ALT-801) (GLP-1R/GCGR)DetailsType 2 diabetes Phase 1b
AdCOVIDDetailsCOVID-19 Failed
NasoShield (Vaccine)DetailsAnthrax, Bacterial infection Failed
HepTCellDetailsChronic hepatitis B Failed
T-COVIDDetailsCOVID-19 Failed
NasoVAXDetailsInfluenza Failed

Market Data


Open $2.77
Previous Close $2.87
Volume 2.2M
Market Cap $573.70M
Day Range $2.75 - $2.96
52 Week Range $2.56 - $6.44
Shares Outstanding 194.47M
Change % -3.66%
Net Change ▼ -0.1050
Insider Ownership -0.05%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology
IPO Year2005
CountryUnited States

Insider Ownership Transactions

Total Amount Purchased: -1,445,994.00

Date Type Amount Purchased Purchaser
2024-02-01 Sale -9275.00 Eisenstadt Richard I
2024-02-01 Sale -9275.00 Roberts M Scot
2024-01-29 Sale -163200.00 Eisenstadt Richard I
2024-01-29 Sale -163200.00 Roberts M Scot
2024-01-29 Sale -163200.00 Jordt Raymond M
2024-01-29 Sale -163200.00 Harris Matthew Scott
2024-01-29 Sale -470000.00 Garg Vipin K
2024-01-04 Sale -9375.00 Jordt Raymond M
2024-01-02 Sale -12500.00 Eisenstadt Richard I
2023-09-29 Sale -26100.00 Hodges Philip

SEC Filings


Form Type Description Pages Date
4 Insider transactions 1 Nov 12, 2025
8-k 8K-related 14 Nov 06, 2025
10-q Quarterly Reports 62 Nov 06, 2025
8-k 8K-related 14 Nov 06, 2025
8-k 8K-related 12 Oct 03, 2025
4 Insider transactions 1 Oct 03, 2025
3 Insider transactions 2 Oct 03, 2025
4 Insider transactions 1 Oct 03, 2025
4 Insider transactions 2 Sep 29, 2025
4 Insider transactions 1 Sep 29, 2025

Latest News